These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31519585)

  • 1. mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both
    Liao HF; Lin YZ; Yu CC; Tai TS; Hung SK; Yang CC; Su YC
    Anticancer Res; 2019 Sep; 39(9):4829-4835. PubMed ID: 31519585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
    Li S; Sheng J; Liu Z; Fan Y; Zhang C; Lv T; Hu S; Jin J; Yu W; Song Y
    J Cell Mol Med; 2021 Mar; 25(5):2436-2449. PubMed ID: 33507584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
    Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL
    Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
    Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
    Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
    Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
    Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
    Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
    Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.
    Fantus D; Dai H; Ono Y; Watson A; Yokota S; Mohib K; Yoshida O; Ross MA; Watkins SC; Ramaswami B; Valusjkikh A; Rothstein DM; Thomson AW
    Transplantation; 2017 Dec; 101(12):2830-2840. PubMed ID: 28885497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
    Mizutani Y; Inase A; Maimaitili Y; Miyata Y; Kitao A; Matsumoto H; Kawaguchi K; Higashime A; Goto H; Kurata K; Yakushijin K; Minami H; Matsuoka H
    Int J Hematol; 2019 Oct; 110(4):490-499. PubMed ID: 31286402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory.
    MacCallum PE; Blundell J
    Psychopharmacology (Berl); 2020 Sep; 237(9):2795-2808. PubMed ID: 32601986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
    Li X; Li Z; Song Y; Liu W; Liu Z
    Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
    Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
    Hu X; Wang Z; Chen M; Chen X; Liang W
    Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
    Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
    Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
    Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
    Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.
    Xie Y; Li B; Bu W; Gao L; Zhang Y; Lan X; Hou J; Xu Z; Chang S; Yu D; Xie B; Wang Y; Wang H; Zhang Y; Wu X; Zhu W; Shi J
    Int J Oncol; 2018 Aug; 53(2):823-834. PubMed ID: 29901111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one derivatives as mTORC1/mTORC2 dual inhibitors.
    Hu S; Zhao Z; Yan H
    Bioorg Chem; 2019 Nov; 92():103232. PubMed ID: 31526911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
    J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.
    Kim JO; Kim KH; Song IS; Cheon KS; Kim OH; Lee SC; Lee SK; Kim SJ
    Oncotarget; 2017 Jan; 8(2):2936-2948. PubMed ID: 27935857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.